Experimental study reveals a scalable synthesis for a chiral tetralol intermediate of udifitimod, indicating a viable alternative to cryogenic manufacturing.
Herein, we describe a two-step alkylation and asymmetric transfer hydrogenation telescope process for the synthesis of an enantioenriched substituted tetralol, a key intermediate in the synthesis of active pharmaceutical ingredient udifitimod (BMS-986166). A hydrogen borrowing alkylation catalyzed by an iridium catalyst was developed to replace an asymmetric alkylation that utilized an alkyl iodide with a costly stoichiometric chiral auxiliary under cryogenic conditions. In the following step, construction of the key stereocenter on the tetralin core was enabled by dynamic kinetic resolution using Ru-catalyzed asymmetric transfer hydrogenation. Process optimization allowed for a telescoped process that delivered the chiral alcohol product with high yield, purity, and enantio- and diastereoselectivity as well as controlled levels of residual metal content acceptable for downstream processing.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: